Responsiveness of hypercalciuria to thiazide in Dent's disease.
Hypercalciuria is the major risk factor promoting stone formation in Dent's disease, also known as X-linked recessive nephrolithiasis, but the effects of diuretics on calcium excretion and other stone risk factors in this disease are unknown. This study examined urine composition in eight male patients with Dent's disease, ages 6 to 49 yr, all of whom were hypercalciuric and had inactivating mutations of CLCN5. Eight males, ages 7 to 34 yr, with idiopathic hypercalciuria (IH) served as controls. Patients were instructed to maintain a consistent intake of sodium, potassium, calcium, and protein. Two consecutive 24-h urine collections were obtained after a baseline period and after 2 wk of chlorthalidone (25 mg), amiloride (5 mg), and the two diuretics in combination, with a week off drug separating the treatment periods in a randomized crossover design. Doses were reduced by half in boys under age 12 yr. Chlorthalidone alone (P < 0.002) and the combination of chlorthalidone and amiloride (P < 0.003) reduced calcium excretion significantly in either patient group. With chlorthalidone, calcium excretion fell to normal (<4.0 mg/kg per d) in all but one patient in each group. Amiloride alone had no significant effect on urinary calcium excretion, in either patient group. In patients with Dent's disease during chlorthalidone therapy, the supersaturation ratios for calcium oxalate and calcium phosphate fell by 25% and 35%, respectively. Mean citrate excretion was reduced by chlorthalidone (P <.04) and by chlorthalidone in combination with amiloride (P <.02). There were no significant differences in the responses to these diuretics between the patient groups in any of the urinary parameters. The intact hypocalciuric response to a thiazide diuretic indicates that inactivation of the ClC-5 chloride channel does not impair calcium transport in the distal convoluted tubule and indicates that thiazides should be useful in reducing the risk of kidney stone recurrence in patients with Dent's disease.
Raja
Khalid A
KA
Departments of Medicine and Pediatrics, SUNY Upstate Medical University, 750 E. Adams Street, Syracuse, NY 13210, USA.
Schurman
Scott
S
D'mello
Richard G
RG
Blowey
Douglas
D
Goodyer
Paul
P
Van Why
Scott
S
Ploutz-Snyder
Robert J
RJ
Asplin
John
J
Scheinman
Steven J
SJ
D000293:Adolescent; D000328:Adult; D000584:Amiloride / Q000627:therapeutic use*; D002118:Calcium / Q000652:urine*; D002129:Calcium Oxalate / Q000652:urine; D002648:Child; D002752:Chlorthalidone / Q000627:therapeutic use*; D041321:Chromosomes, Human, X; D018592:Cross-Over Studies; D004232:Diuretics / Q000627:therapeutic use*; D004338:Drug Combinations; D008040:Genetic Linkage; D006801:Humans; D007669:Kidney Calculi / Q000188:drug therapy* / Q000235:genetics* / Q000652:urine; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration
D004232:Diuretics; D004338:Drug Combinations; D002129:Calcium Oxalate; D000584:Amiloride; D002752:Chlorthalidone; D002118:Calcium